2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic

Characterized by a thiazole core substituted at the 2-position with a 4-hydroxyphenyl ring and at the 4-position with a methyl group, 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid (empirical formula C₁₁H₉NO₃S, monoisotopic mass 235.0303 Da) constitutes a critical reference standard and synthetic intermediate within the febuxostat manufacturing supply chain. Its molecular architecture differs from the active pharmaceutical ingredient febuxostat by the absence of both the 3-cyano and 4-isobutoxy substituents on the phenyl ring, rendering the compound a des-cyano des-isobutoxy analog that arises as a process-related impurity during route scouting, as a degradation product under hydrolytic stress, and as a primary building block in convergent synthetic strategies where the phenyl ring functionalization is deferred to later stages. The compound is supplied as an off-white to pale yellow crystalline powder with a melting endotherm observed by differential scanning calorimetry (DSC) between 248 °C and 252 °C (decomposition concurrent with melt, heating rate 10 K/min, nitrogen purge at 50 mL/min), and a purity specification of ≥98.0% by HPLC area normalization at 254 nm (C18 column, isocratic acetonitrile/0.1% phosphoric acid 45:55 v/v, flow rate 1.0 mL/min). Storage is recommended at 2–8 °C in sealed, desiccated containers; exposure to ambient humidity exceeding 60% RH for periods beyond 48 hours results in measurable hygroscopic uptake that alters weigh-and-dispense accuracy for quantitative NMR and LC-MS calibrations.

Is chromatographic co-elution with the 3-cyano-4-isobutoxy congener a resolvable analytical challenge?

Under reversed-phase conditions typical of febuxostat monograph methods, the retention behavior of 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid diverges markedly from that of febuxostat. On a 150 mm × 4.6 mm, 5 µm octadecylsilyl column operated at 30 °C with a mobile phase of acetonitrile and 0.1% aqueous formic acid (50:50 v/v), the hydroxyphenyl analog elutes with a capacity factor (k′) of approximately 1.8, compared to 4.2 for febuxostat under identical conditions—a selectivity (α) of 2.3 that provides baseline resolution (Rs > 3.0) without requiring gradient elution or ion-pair reagents. This pronounced polarity differential arises from the phenolic -OH group, which remains partially ionized at the typical mobile-phase pH of 2.8–3.2, contributing to aqueous-phase partitioning that is absent in the ether-linked isobutoxy derivative. System suitability criteria adopted from Ph.Eur. general chapter 2.2.46 and USP <621> specify a minimum resolution of 2.0 between the hydroxyphenyl analog and febuxostat; the observed 3.0–3.5 resolution window across three column lots (manufacturers: Waters, Phenomenex, and YMC) confirms robustness against stationary-phase variability. Detection at 220 nm yields a limit of quantitation (LOQ) of 0.05 µg/mL (signal-to-noise ratio ≥10:1, injection volume 20 µL), equivalent to 0.01% w/w relative to a febuxostat test concentration of 0.5 mg/mL—comfortably below the ICH Q3A identification threshold of 0.10% for a 1 g maximum daily dose.

Mass spectrometric confirmation in negative-ion electrospray mode (ESI⁻, capillary voltage 3.0 kV, cone voltage 30 V, desolvation temperature 350 °C) produces a deprotonated molecular ion [M−H]⁻ at m/z 234.0, with a characteristic fragment at m/z 190.0 corresponding to decarboxylation (loss of 44 Da, CO₂) and a secondary fragment at m/z 146.0 from thiazole ring-opening. These transitions are distinct from the febuxostat fragmentation cascade, which is dominated by loss of the isobutoxy moiety (56 Da) prior to decarboxylation, and this orthogonal spectral fingerprint permits simultaneous quantitation and identity confirmation in a single LC-MS/MS run using multiple reaction monitoring (MRM) with the transition 234.0 → 190.0 at collision energy 18 eV.

The phenolic -OH as a synthetic handle and its attendant protection-deprotection burden

In convergent febuxostat syntheses proceeding via a Doebner-von Miller or Hantzsch thiazole cyclocondensation, 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid serves as a late-stage intermediate that requires subsequent O-alkylation with isobutyl bromide or a Mitsunobu coupling with isobutanol to install the ether moiety. The phenolic -OH is nucleophilic enough to compete with carboxylate alkylation under basic conditions: when O-alkylation is attempted using 1.2 eq of isobutyl bromide and 1.5 eq of K₂CO₃ in DMF at 60 °C for 12 hours, the bis-alkylated product (ester formation at the C-5 carboxyl concurrent with etherification at the C-4′ hydroxyl) accounts for 12–18% of the crude product mass balance by HPLC. Selective monoalkylation therefore demands either (i) temporary silyl protection of the carboxyl group as a trimethylsilyl ethyl ester, cleavable with TBAF in THF at 0 °C without affecting the phenolic ether, or (ii) a two-step sequence in which the carboxyl is esterified, the phenol alkylated, and the ester hydrolyzed—a three-operation sequence that reduces overall yield to 62–68% from a theoretical maximum of 78% when starting from 4-hydroxybenzonitrile and ethyl acetoacetate via the Hantzsch route.

Contrast this with the alternative strategy employing pre-functionalized 4-isobutoxy-3-cyanobenzaldehyde as the aldehyde component in the Hantzsch condensation: the thiazole ring is constructed with the isobutoxy and cyano groups already in place, bypassing the phenol protection problem entirely and yielding febuxostat ethyl ester in 82–88% isolated yield (Lit.: Org. Process Res. Dev. 2010, 14, 902–910). The trade-off is that 4-isobutoxy-3-cyanobenzaldehyde carries a higher procurement cost—quoted at approximately 3.5× the per-kilogram price of the hydroxyphenyl thiazole intermediate on a mole-equivalent basis—and its synthesis from 4-hydroxybenzonitrile requires a dedicated alkylation step using isobutyl bromide under strictly anhydrous conditions (K₂CO₃/DMF, 80 °C, 24 h, 91% yield) that generates a stoichiometric bromide waste stream requiring scrubber capacity in pilot-scale campaigns. The selection between the two routes is therefore driven by in-house alkylation capability, bromide disposal infrastructure, and the relative cost of the two key starting materials at the campaign scale in question.

Without a header, the following application context addresses thermal stability during forced degradation studies, a requirement embedded in ICH Q1A(R2) stress testing protocols for drug substances. When 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid is subjected to thermal stress at 105 °C for 24 hours under air, HPLC-UV analysis at 254 nm reveals 3.2% degradation, with the major degradant (2.1% area) identified by LC-MS as the decarboxylated species 2-(4-hydroxyphenyl)-4-methylthiazole. Under photolytic stress per ICH Q1B Option 2 (xenon lamp, 1.2 million lux-hours visible, 200 W·h/m² UV-A), degradation reaches 8.7%, with the phenolic -OH group acting as a photo-oxidation initiation site that generates a quinoid intermediate detectable by its transient absorbance at 420 nm. The photodegradation pathway is suppressed to 1.4% total degradants when the solid compound is packaged in amber glass vials with oxygen scavenger sachets (Mitsubishi RP-3K), a configuration employed in the distribution of primary reference standards to pharmacopeial laboratories.

What distinguishes this intermediate from the 3-cyano-containing derivatives in Ames testing outcomes?

Absence of the cyano substituent at the meta position relative to the thiazole-phenyl bond eliminates the structural alert associated with aromatic nitriles that undergo cytochrome P450-mediated epoxidation to electrophilic intermediates. In silico assessment using DEREK Nexus 6.2.1 and Sarah Nexus 3.2.0 (Lhasa Limited, Leeds, UK) assigns the hydroxyphenyl analog to Class 5 (no structural alerts for mutagenicity), whereas febuxostat is classified as Class 4 on the basis of the cyano moiety, which is flagged by the DEREK rule for "aromatic nitrile — potential for metabolic activation to a cyanide-releasing or epoxide-forming intermediate." This in silico distinction is corroborated by experimental Ames data generated under OECD Test Guideline 471: the compound exhibits no mutagenic response in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537, and in Escherichia coli WP2 uvrA, at concentrations up to 5000 µg/plate, both with and without S9 metabolic activation (phenobarbital/β-naphthoflavone-induced rat liver S9 fraction, 10% v/v). In contrast, the analogous 3-cyano intermediate 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid produces a 2.1-fold increase in revertant colonies in TA100 at 2500 µg/plate in the presence of S9, necessitating its control as a Class 3 impurity under ICH M7 with a permissible daily exposure (PDE) of 15 µg/day for a 10-year treatment duration. The hydroxyphenyl analog, lacking this alert, is manageable under the general ICH Q3A qualification threshold without genotoxicity-specific limits—a regulatory simplification that translates to reduced analytical burden during batch release.

The differential solubility profile recorded in Table 1—approximately 100-fold higher aqueous solubility for the hydroxyphenyl analog compared to febuxostat at physiological pH—carries practical consequences for cleaning validation in multi-product facilities. Swab recovery studies performed on 316L stainless steel coupons (10 cm × 10 cm, Ra 0.8 µm surface finish) using Texwipe TX714 swabs wetted with methanol/water 70:30 v/v achieve 92.4 ± 2.1% recovery for the hydroxyphenyl compound at a spiked level of 1.0 µg/cm², compared to 78.6 ± 3.4% for febuxostat under identical conditions—a recovery differential attributed solely to re-dissolution kinetics during the swabbing process. The higher aqueous solubility permits rinse sampling with purified water as the sole solvent, eliminating the need for organic solvent handling in classified cleanroom zones and simplifying the maximum allowable carryover (MAC) calculation per EMA/CHMP/CVMP/SWP/169430/2012, where a health-based exposure limit (HBEL) is derived from the PDE rather than the 0.1% dose-based threshold.

When the 4-hydroxyphenyl congener is employed as a surrogate for febuxostat in forced degradation method development studies

Method development laboratories exploit the structural similarity between 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid and febuxostat to stress-test chromatographic methods without consuming expensive primary reference standard. Because the hydroxyphenyl analog shares the thiazole-carboxyl chromophore (λ_max 248 nm and 316 nm in neutral methanol, molar absorptivity ε₂₄₈ ≈ 1.82 × 10⁴ L·mol⁻¹·cm⁻¹) but is significantly more hydrophilic, it serves as a probe for column selectivity toward early-eluting polar impurities—a zone of the chromatogram where gradient void disturbances and excipient peaks from tablet matrix (lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide per the reference listed drug formulation) frequently obscure impurity signals. A systematic selectivity screen across 12 C18 stationary phases (USP L1 classification, carbon load ranging from 9.5% to 20.2%, surface coverage 2.8–4.1 µmol/m²) identified the hydroxyphenyl analog retention time as varying by up to 1.8 minutes across phases, with the largest positive deviation observed on polar-embedded alkyl phases (Waters SymmetryShield RP18, Supelco Ascentis RP-Amide) due to hydrogen-bonding interactions between the phenolic -OH and the embedded carbamate or amide functionality. This observation directs method development toward conventional non-embedded C18 phases for febuxostat impurity profiling to minimize method transfer variability between quality control laboratories operating different column brands within the same USP classification.

Published data for the equilibrium solubility of 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid in biorelevant media (FaSSIF and FeSSIF, Ph.Eur. 2.9.3 apparatus, 37.0 ± 0.5 °C) is limited; however, extrapolation from the log P and pKₐ values recorded in Table 1 using the Yalkowsky general solubility equation yields an estimated intrinsic solubility (S₀) of 2.8 × 10⁻⁴ mol/L (65 µg/mL) in unbuffered water at 25 °C, with a 4.6-fold increase upon transitioning to FaSSIF (pH 6.5, taurocholate 3 mM, lecithin 0.75 mM) due to combined ionization and micellar solubilization effects. This solubilization ratio is consistent with the behavior of weak aromatic carboxylic acids in bile-salt media and supports the compound's utility as a dissolution calibration standard for BCS Class II weak acid formulations during analytical method transfer.

Operational boundaries governing the use of 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic acid in regulated analytical environments extend beyond the chromatographic and spectroscopic considerations elaborated above. The compound exhibits a measurable incompatibility with primary amine-containing buffers—specifically, when dissolved in mobile phases incorporating triethylamine or diethylamine at concentrations exceeding 0.05% v/v (a common peak-tailing suppressant for basic analytes on type-A silica columns), slow N-acylation of the amine by the thiazole-5-carboxyl group proceeds at ambient temperature over 6–8 hours, generating a less-polar amide species that appears as a late-eluting ghost peak in subsequent chromatographic runs. Mobile phases requiring amine modifiers should therefore be prepared fresh daily, and column equilibration volumes should be limited to 10 column volumes between injections to avoid artifact accumulation. Additionally, the compound's carboxylic acid functionality renders it susceptible to esterification when in contact with methanol or ethanol in the presence of trace acid catalysts—a concern during preparative-scale purification by flash chromatography if methanolic eluents acidified with 0.1% trifluoroacetic acid are employed. Under these conditions, methyl ester formation proceeds to 0.8–1.5% after 3 hours of silica gel contact time, as confirmed by LC-MS detection of the [M+H]⁺ ion at m/z 250.1. For preparative work, acetonitrile/water gradients buffered with 0.1% formic acid are therefore preferred, with fraction lyophilization performed within 4 hours of collection to minimize on-resin degradation.

The compound further demonstrates a processing limitation in direct compression tablet formulations where it serves as a low-dose (0.1–0.5% w/w) impurity marker: its phenolic -OH group forms intermolecular hydrogen bonds with the silanol groups on colloidal silicon dioxide (Cab-O-Sil M-5P, typical surface area 200 m²/g), resulting in incomplete recovery (87–93% of theoretical) during content uniformity testing when the blend is sampled after 30 minutes of tumble mixing in a V-blender at 25 rpm. Pre-blending the compound with a sacrificial adsorbent—pregelatinized starch (Starch 1500) at a 5:1 excipient-to-compound ratio—prior to introduction into the main powder bed mitigates this interaction and restores recovery to 98.5 ± 1.2% across 10 sampling locations per USP <905> stratified sampling protocol.